Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTKB NASDAQ:LAB NASDAQ:QTRX NASDAQ:SIBN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTKBCytek Biosciences$4.01+1.3%$4.36$2.37▼$6.18$511.40M1.221.02 million shs853,530 shsLABStandard BioTools$1.03-1.0%$0.95$0.87▼$1.72$405.98M1.322.05 million shs1.15 million shsQTRXQuanterix$2.69+1.9%$3.44$2.39▼$8.77$124.36M1.151.49 million shs814,980 shsSIBNSiBone$14.68-0.9%$13.39$11.48▼$21.89$656.81M0.67885,427 shs306,450 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTKBCytek Biosciences+5.04%+17.86%-14.47%-10.61%+59.68%LABStandard BioTools-1.89%+4.03%+8.58%-7.96%0.00%QTRXQuanterix+4.76%-4.69%-18.01%-54.17%-45.11%SIBNSiBone-0.07%+1.44%+7.16%-4.33%-22.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTKBCytek Biosciences$4.01+1.3%$4.36$2.37▼$6.18$511.40M1.221.02 million shs853,530 shsLABStandard BioTools$1.03-1.0%$0.95$0.87▼$1.72$405.98M1.322.05 million shs1.15 million shsQTRXQuanterix$2.69+1.9%$3.44$2.39▼$8.77$124.36M1.151.49 million shs814,980 shsSIBNSiBone$14.68-0.9%$13.39$11.48▼$21.89$656.81M0.67885,427 shs306,450 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTKBCytek Biosciences+5.04%+17.86%-14.47%-10.61%+59.68%LABStandard BioTools-1.89%+4.03%+8.58%-7.96%0.00%QTRXQuanterix+4.76%-4.69%-18.01%-54.17%-45.11%SIBNSiBone-0.07%+1.44%+7.16%-4.33%-22.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTKBCytek Biosciences 2.33Hold$5.6941.83% UpsideLABStandard BioTools 1.67Reduce$1.3531.07% UpsideQTRXQuanterix 1.67Reduce$4.0048.70% UpsideSIBNSiBone 2.71Moderate Buy$23.0056.68% UpsideCurrent Analyst Ratings BreakdownLatest QTRX, SIBN, CTKB, and LAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026QTRXQuanterix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026CTKBCytek Biosciences StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$5.50 ➝ $4.755/12/2026CTKBCytek Biosciences Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$6.00 ➝ $5.505/12/2026SIBNSiBone TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$22.00 ➝ $18.005/12/2026SIBNSiBone Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.00 ➝ $18.005/11/2026LABStandard BioTools Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D+)5/7/2026QTRXQuanterix TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$7.00 ➝ $4.004/24/2026LABStandard BioTools Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026QTRXQuanterix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026QTRXQuanterix Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$8.00 ➝ $4.004/15/2026SIBNSiBone Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$24.00 ➝ $20.00(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTKBCytek Biosciences$201.49M2.57N/AN/A$2.54 per share1.58LABStandard BioTools$85.33M4.71N/AN/A$1.44 per share0.72QTRXQuanterix$138.90M0.91N/AN/A$5.99 per share0.45SIBNSiBone$200.93M3.24N/AN/A$4.03 per share3.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTKBCytek Biosciences-$66.54M-$0.57N/AN/AN/A-36.25%-10.07%-7.56%8/5/2026 (Estimated)LABStandard BioTools-$74.90M$0.205.15N/AN/A73.46%-8.18%-6.43%8/10/2026 (Estimated)QTRXQuanterix-$107.15M-$2.36N/AN/AN/A-71.86%-23.92%-17.66%8/6/2026 (Estimated)SIBNSiBone-$18.90M-$0.39N/AN/AN/A-8.10%-9.56%-7.06%8/3/2026 (Estimated)Latest QTRX, SIBN, CTKB, and LAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026SIBNSiBone-$0.17-$0.10+$0.07-$0.10$51.16 million$52.59 million5/7/2026Q1 2026CTKBCytek Biosciences-$0.08-$0.15-$0.07-$0.15$44.23 million$44.14 million5/6/2026Q1 2026QTRXQuanterix-$0.5133-$0.39+$0.1233-$0.37$36.84 million$35.90 million3/2/2026Q4 2025QTRXQuanterix-$0.27-$0.38-$0.11-$0.49$37.95 million$41.40 million2/26/2026Q4 2025CTKBCytek Biosciences$0.02-$0.34-$0.36-$0.34$58.80 million$62.14 million2/24/2026Q4 2025LABStandard BioTools-$0.03$0.05+$0.08$0.05$18.50 million$23.80 million2/23/2026Q4 2025SIBNSiBone-$0.13-$0.04+$0.09-$0.04$56.26 million$56.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTKBCytek BiosciencesN/AN/AN/AN/AN/ALABStandard BioToolsN/AN/AN/AN/AN/AQTRXQuanterixN/AN/AN/AN/AN/ASIBNSiBoneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTKBCytek BiosciencesN/A4.694.07LABStandard BioToolsN/A12.3611.92QTRXQuanterixN/A3.722.70SIBNSiBone0.209.998.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTKBCytek Biosciences69.46%LABStandard BioTools53.74%QTRXQuanterix86.48%SIBNSiBone98.11%Insider OwnershipCompanyInsider OwnershipCTKBCytek Biosciences10.36%LABStandard BioTools23.16%QTRXQuanterix1.50%SIBNSiBone4.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTKBCytek Biosciences500129.14 million115.76 millionOptionableLABStandard BioTools620390.37 million299.96 millionOptionableQTRXQuanterix46047.11 million46.40 millionOptionableSIBNSiBone35044.35 million42.58 millionOptionableQTRX, SIBN, CTKB, and LAB HeadlinesRecent News About These CompaniesSiBone (NASDAQ:SIBN) SVP Sells 3,726 SharesMay 21 at 8:07 AM | insidertrades.comAnshul Maheshwari, CFO of SI-BONE, sells $60k in SIBN stockMay 15, 2026 | investing.comHow Much Upside is Left in Si-Bone (SIBN)? Wall Street Analysts Think 65.27%May 15, 2026 | zacks.comSiBone $SIBN Shares Bought by HighMark Wealth Management LLCMay 14, 2026 | marketbeat.comSI-BONE targets $230M-$233M 2026 revenue while CMS proposes new DRGs that could add up to $50,000 per Granite procedureMay 14, 2026 | seekingalpha.comSiBone (NASDAQ:SIBN) Given Buy Rating at Truist FinancialMay 13, 2026 | americanbankingnews.comSI-BONE, Inc. (SIBN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comSI-BONE, Inc. (SIBN) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comSI-BONE, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 12, 2026 | seekingalpha.comSI-BONE, Inc. (NASDAQ:SIBN) Q1 2026 Earnings Call TranscriptMay 12, 2026 | insidermonkey.comSiBone Q1 Earnings Call HighlightsMay 11, 2026 | marketbeat.comSi-Bone (SIBN) Reports Q1 Loss, Tops Revenue EstimatesMay 11, 2026 | zacks.comSI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 GuidanceMay 11, 2026 | globenewswire.comSiBone (SIBN) Expected to Announce Earnings on MondayMay 4, 2026 | marketbeat.comHussman Strategic Advisors Inc. Purchases Shares of 84,000 SiBone $SIBNMay 3, 2026 | marketbeat.comSiBone (NASDAQ:SIBN) Receives Average Rating of "Moderate Buy" from AnalystsMay 1, 2026 | marketbeat.comSI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026April 30, 2026 | globenewswire.comSiBone (NASDAQ:SIBN) Short Interest UpdateApril 30, 2026 | marketbeat.comSiBone (NASDAQ:SIBN) Hits New 52-Week Low - Time to Sell?April 29, 2026 | marketbeat.comImpax Asset Management Group plc Has $23.66 Million Stock Holdings in SiBone $SIBNApril 25, 2026 | marketbeat.comSI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026April 20, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQTRX, SIBN, CTKB, and LAB Company DescriptionsCytek Biosciences NASDAQ:CTKB$4.01 +0.05 (+1.26%) Closing price 04:00 PM EasternExtended Trading$3.97 -0.04 (-1.00%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.Standard BioTools NASDAQ:LAB$1.03 -0.01 (-0.96%) Closing price 04:00 PM EasternExtended Trading$1.03 0.00 (0.00%) As of 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.Quanterix NASDAQ:QTRX$2.69 +0.05 (+1.89%) Closing price 04:00 PM EasternExtended Trading$2.76 +0.07 (+2.57%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.SiBone NASDAQ:SIBN$14.68 -0.13 (-0.88%) Closing price 04:00 PM EasternExtended Trading$15.28 +0.60 (+4.05%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Intuit's Great SaaS Reset: Fired By AI Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Target Shows Strengths, But Analysts Want to See More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
